Clinical trials
Magnetic Resonance clinical trials
Below are recruiting magnetic resonance clinical trials, each written for real people, not researchers. We’re tracking 809 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07001748RecruitingPhase 2/Phase 3
Testing abdominal chemo plus standard chemo for stomach cancer spread
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT07012031RecruitingPhase 1/Phase 2
Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer
This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07016399RecruitingPhase 2
Darolutamide before surgery for AR-positive triple-negative breast cancer
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Nashville, TennesseeAges 18 years+ - NCT07033923Recruiting
Brain study of mood changes in depression and bipolar disorder
This study uses a mobile app and brain scans to understand day-to-day mood changes in people with depression or bipolar disorder. It may help doctors learn how to better predict and treat these conditions.
Paris, ParisAges 18 years+ - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07044596Recruiting
Non-invasive brain stimulation to slow cognitive decline
This study tests whether a gentle, non-invasive electrical stimulation can help slow memory loss or thinking problems. It is looking for healthy volunteers and people who have had a mild traumatic brain injury within the past year.
Madison, WisconsinAges 20–85 - NCT07061821Recruiting
Faster heart MRI with AI for left ventricular hypertrophy
This study tests a faster cardiac MRI scan that uses artificial intelligence to speed up the imaging process. It is for patients who need a heart MRI to check or follow up on left ventricular hypertrophy (thickening of the heart muscle).
AmiensAges 18 years+ - NCT07067749RecruitingPhase 3
MRI-guided treatment for muscle invasive bladder cancer
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
Rome, RMAges 18 years+ - NCT07069452Recruiting
Predicting recovery after stroke with brain scan scores
This study looks at how well different scores from brain scans can predict recovery after a stroke. It is for people who had an ischemic stroke and were treated with both clot-dissolving medicine and a clot removal procedure.
GonesseAges 18 years+ - NCT07071272Recruiting
Comparing two breast imaging methods before surgery
This trial compares a special mammogram with dye (CEDM) to MRI for women already diagnosed with invasive breast cancer. The goal is to see if CEDM works as well as MRI for planning surgery, potentially offering a faster or easier option.
Verona, ItalyAges 30 years+ - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT07089940RecruitingEarly Phase 1
OMO-103 for advanced pancreatic cancer
This trial tests a new drug called OMO-103 in people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It may be an option whether you have had treatment before or not, as long as it's been at least 2 weeks since your last therapy.
Portland, OregonAges 18 years+ - NCT07093346Recruiting
Pectin supplement for fatty liver disease
This study tests whether a pectin supplement (a fiber found in fruits) can reduce inflammation and improve liver and metabolic health in people with fatty liver disease (MASLD). You might be eligible if you have MASLD, a healthy weight range, and can avoid certain medications and foods.
NottinghamAges 18 years+ - NCT07097077Recruiting
Brain changes after ACL surgery with special training
This study uses brain scans (fMRI) to see how a special type of movement training affects the brain after ACL surgery. If you've had an ACL repair and are active in sports, you may be eligible.
Bologna, BolognaAges 18–30 - NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Fort Smith, ArkansasAges 18 years+ - NCT07103733Recruiting
Adding MRI and monitoring to mitral valve repair study
This study is for people already in the PRIMARY trial who are having mitral valve repair surgery. It adds an extra MRI scan and possibly a heart rhythm monitor to learn more about heart recovery after repair.
Los Angeles, CaliforniaAges 60 years+ - NCT07107919Recruiting
Imaging heart and kidney health in chronic kidney disease
This study uses advanced imaging (PET/MRI) to look at how kidney disease affects the heart and blood vessels. It may help doctors better understand and treat chronic kidney disease.
Qingdao, ShandongAges 18–80 - NCT07118137Recruiting
Memory loss in Alzheimer's disease study
This study looks at how memory changes over time in people with Alzheimer's or mild memory problems. It uses advanced brain scans to understand the disease better.
Trondheim, TrønderlagAges 55 years+ - NCT07128680RecruitingPhase 1
Immunotherapy with or without a gut bacteria pill for kidney cancer
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
Duarte, CaliforniaAges 18 years+ - NCT07131631Recruiting
MitraClip for leaky heart valve in heart failure patients
This trial tests if the MitraClip device helps people with heart failure and a leaky mitral valve. It uses a special MRI to check how the heart responds to treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT07137936Recruiting
Heart MRI Scar Study to Predict Sudden Cardiac Arrest Risk
This study uses a special heart MRI to look at scar tissue after a heart attack and see if it can help predict who might need a device to prevent sudden cardiac arrest. It is for people who had a heart attack at least a month ago and had a cardiac MRI at Anzhen Hospital.
BeijingAges 18–80 - NCT07155317RecruitingPhase 2
Time-of-day immunotherapy for advanced melanoma
This trial tests whether giving immunotherapy at a specific time of day can improve its effectiveness for advanced melanoma that cannot be removed by surgery. It may help you if you have stage IV melanoma and have not had immunotherapy in the last year.
Atlanta, GeorgiaAges 18 years+ - NCT07166406RecruitingPhase 3
Immunotherapy with or without targeted radiation for advanced liver cancer
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
Berkeley, CaliforniaAges 18 years+ - NCT07174570RecruitingPhase 2
Celecoxib with immunotherapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Atlanta, GeorgiaAges 18 years+
Hear when a new Magnetic Resonance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for magnetic resonance?
- Yes. Clin2 currently lists 809 recruiting magnetic resonance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a magnetic resonance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a magnetic resonance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.